SecBot SecBot

DBVTF

DBV Technologies S.A.
OTC· Biological Products, (No Diagnostic Substances)· Inc. I0· CIK 0001613780 Biotech & Drug Discovery
$1.98 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $1.98
1 year
+1979900.1%
from $0.00010000 · Oct 27
30 days
−21.2%
from $2.51
52-week range
$0.00010000–4.80
−59% from high · low Oct 27
Avg volume 20D
195
Oct 2 spike 1.9K
Short interest
476.9K
−11.3%
Days to cover
5.3
at average volume
Filing reports
2
analyzed by SecBot
SecBot read MIXED 2 reports · latest
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest NEUTRAL DBV Technologies reported Q1 2026 financial results, showing a net loss of $47.6M, widening from $27.1M in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

  • X Aug 14 Short interest jumps 343.1% to 183.3K
  • X Aug 31 Short interest jumps 127.9% to 417.7K
  • X Sep 15 Short interest jumps 28.7% to 537.6K

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest −11.3% to 476.9K shares. 5.3 days to cover.

  • TrendDOWNTREND

    35% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 5, 2026 SEC
DBV Technologies granted CEO Daniel Tass 4,060,000 performance share units (PSUs) tied to FDA approval of Viaskin…
8-K — Impact 2/10
Apr 30, 2026 SEC
DBV Technologies reported Q1 2026 financial results, showing a net loss of $47.6M, widening from $27.1M in Q1 2025…
8-K — Impact 4/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$581.6K
Next Q———$581.6K
Current FY———$3.6M
Next FY———$62.3M

Short side

FINRA· Sep 30, 2026
476,872
shares short
-11.3%
vs prior settlement
5.3
days to cover

SecBot reports

2 filings · 0 bullish · 0 bearish · 2 neutral
All DBVTF filing & press-release reports (2)